Attenuation of the TGF-β-Smad signaling pathway in pancreatic tumor cells confers resistance to TGF-β-induced growth arrest

We have investigated the mechanism whereby tumor cells become resistant to the antiproliferative effects of transforming growth factor (TGF)-β, while maintaining other responses that can lead to increased malignancy and invasiveness. TGF-β signaling results in nuclear accumulation of active Smad complexes which regulate transcription of target genes. Here we show that in two pancreatic carcinoma cell lines, PT45 and Panc-1, that are resistant to TGF-β-induced growth arrest, the TGF-β-Smad signaling pathway is attenuated compared with epithelial cells that are sensitive to the antiproliferative effects of TGF-β (HaCaT and Colo-357). In PT45 and Panc-1 cells, active Smad complexes remain nuclear for only 1–2 h compared with more than 6 h in HaCaT and Colo-357 cells. The attenuated pathway in PT45 and Panc-1 cells correlates with low levels of TGF-β type I receptor and results in an altered expression profile of TGF-β-inducible genes required for cell cycle arrest. Most significantly, expression of the CDK inhibitor, p21Cip1/WAF1, which is required for TGF-β-induced growth arrest in these cells, is not maintained. Moreover, we show that artificially attenuating the TGF-β-Smad signaling pathway in HaCaT cells is sufficient to prevent TGF-β-induced growth arrest. Our results demonstrate that the duration of TGF-β-Smad signaling is a critical determinant of the specificity of the TGF-β response.

[1]  C. Hill,et al.  Nucleocytoplasmic shuttling of Smads 2, 3, and 4 permits sensing of TGF-beta receptor activity. , 2002, Molecular cell.

[2]  D. He,et al.  Transforming growth factor beta -inducible independent binding of SMAD to the Smad7 promoter. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[3]  Scott E. Kern,et al.  DPC4, A Candidate Tumor Suppressor Gene at Human Chromosome 18q21.1 , 1996, Science.

[4]  Josette Chen.  Smithsonian closure plan under fire , 2001, Nature.

[5]  J. Kleeff,et al.  Up-regulation of Transforming Growth Factor (TGF)-β Receptors by TGF-β1 in COLO-357 Cells* , 1998, The Journal of Biological Chemistry.

[6]  H. Lodish,et al.  Synergism between Transcription Factors TFE3 and Smad3 in Transforming Growth Factor-β-induced Transcription of theSmad7 Gene* , 2000, The Journal of Biological Chemistry.

[7]  Ruth Lehr,et al.  Identification of novel inhibitors of the transforming growth factor beta1 (TGF-beta1) type 1 receptor (ALK5). , 2002, Journal of medicinal chemistry.

[8]  G. Capellá,et al.  Disruption of the antiproliferative TGF-β signaling pathways in human pancreatic cancer cells , 1998, Oncogene.

[9]  Xiao-Fan Wang,et al.  Functional Analysis of the Transforming Growth Factor βResponsive Elements in the WAF1/Cip1/p21 Promoter (*) , 1995, The Journal of Biological Chemistry.

[10]  A. Reith,et al.  SB-431542 is a potent and specific inhibitor of transforming growth factor-beta superfamily type I activin receptor-like kinase (ALK) receptors ALK4, ALK5, and ALK7. , 2002, Molecular pharmacology.

[11]  J. Gurdon,et al.  A quantitative analysis of signal transduction from activin receptor to nucleus and its relevance to morphogen gradient interpretation. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[12]  M. Ashburner.  A Laboratory manual , 1989 .

[13]  Tomoki Chiba,et al.  Smurf1 Interacts with Transforming Growth Factor-β Type I Receptor through Smad7 and Induces Receptor Degradation* , 2001, The Journal of Biological Chemistry.

[14]  G. G. Stokes.  "J." , 1890, The New Yale Book of Quotations.

[15]  L. Wakefield,et al.  TGF-β signaling: positive and negative effects on tumorigenesis , 2002 .

[16]  J. Massagué,et al.  TGFβ Signaling in Growth Control, Cancer, and Heritable Disorders , 2000, Cell.

[17]  A. Suzuki,et al.  Concentration-dependent patterning of the Xenopus ectoderm by BMP4 and its signal transducer Smad1. , 1997, Development.

[18]  S. R. Hann,et al.  A role for transcriptional repression of p21CIP1 by c-Myc in overcoming transforming growth factor beta -induced cell-cycle arrest. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[19]  J. Gurdon,et al.  Morphogen gradient interpretation , 2001, Nature.

[20]  J. Massagué,et al.  Repression of the CDK activator Cdc25A and cell-cycle arrest by cytokine TGF-β in cells lacking the CDK inhibitor p15 , 1997, Nature.

[21]  M. Laiho,et al.  Enhanced production and extracellular deposition of the endothelial- type plasminogen activator inhibitor in cultured human lung fibroblasts by transforming growth factor-beta , 1986, The Journal of cell biology.

[22]  H. Friess,et al.  The TGF-β signaling inhibitor Smad7 enhances tumorigenicity in pancreatic cancer , 1999, Oncogene.

[23]  S. Kern,et al.  Transforming growth factor‐β responsiveness in DPC4/SMAD4‐null cancer cells , 1999 .

[24]  C. Heldin,et al.  Identification of Smad7, a TGFβ-inducible antagonist of TGF-β signalling , 1997, Nature.

[25]  H. Friess,et al.  Enhanced expression of transforming growth factor β isoforms in pancreatic cancer correlates with decreased survival , 1993 .

[26]  P. Hoodless,et al.  Targeted Disruption in Murine Cells Reveals Variable Requirement for Smad4 in Transforming Growth Factor β-related Signaling* , 2000, The Journal of Biological Chemistry.

[27]  IgM μ-Chain.  Antibodies , 2004, Nature Biotechnology.

[28]  H. Lodish,et al.  Biosynthesis of the type I and type II TGF-beta receptors. Implications for complex formation. , 1997, The Journal of biological chemistry.